Zsuzsanna Suba’s Post

Understanding the pivotal regulatory roles of healthy abdominal fatty tissue in signal transduction may answer the question: how can abundant visceral fat deposition lead to serious, life-threatening diseases,

Understanding the pivotal regulatory roles of healthy abdominal fatty tissue in signal transduction may answer the question: how can abundant visceral fat deposition lead to serious, life-threatening diseases,

Understanding the pivotal regulatory roles of healthy abdominal fatty tissue in signal transduction may answer the question: how can abundant visceral fat deposition lead to serious, life-threatening diseases

Understanding the pivotal regulatory roles of healthy abdominal fatty tissue in signal transduction may answer the question: how can abundant visceral fat deposition lead to serious, life-threatening diseases

Understanding the pivotal regulatory roles of healthy abdominal fatty tissue in signal transduction may answer the question: how can abundant visceral fat deposition lead to serious, life-threatening diseases

Understanding the pivotal regulatory roles of healthy abdominal fatty tissue in signal transduction may answer the question: how can abundant visceral fat deposition lead to serious, life-threatening diseases, such as cardiovascular lesions and malignancies

Our latest paper where we assessed relative contributions of mediators including lipid flux, BCAA and glycoprotein acetyls to waist-hip ratio associated cardiometabolic disease in males and females. https://lnkd.in/gutTWDEq

We're especially thrilled to share the GLORY-1 Phase 3 study results of liver fat content in Chinese adults with overweight or obesity at the #ADA Scientific Sessions 2024. This clinical trial of mazdutide brings us closer to offering improved treatment options for those with metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated fatty liver disease (MAFLD). https://lnkd.in/gdXTAxKp

The liver is the Mother Teresa of organs, and we need to show her more love by proactively screening our at-risk patients for metabolic-associated liver disease! 👑 If you’re not sure how to do this, check out this helpful how-to aimed at Primary Care folks: From the article: “While elevated liver enzymes are a red flag for MASLD and liver fibrosis, reliance on transaminase levels alone is inadequate, and at-risk patients should be screened for liver fibrosis even if their transaminase levels are normal. Current guidelines suggest that FIB-4 or other non-invasive scores should be used periodically to monitor patients at risk for liver fibrosis. Given the high negative predictive value of FIB-4 in ruling out advanced fibrosis, patients with a negative result (FIB-4 <1.3) can be followed up in primary care and undergo a repeat risk assessment every two to three years. Patients with T2DM or two or more cardio-metabolic risk factors should undergo FIB-4 reassessment more closely, at least every one to two years, given the higher risk of MASLD progression.”

If you want to know everything about "Orai1/STIMs Modulators in Pulmonary Vascular Diseases", read our well-illustrated review article published in Cell Calcium #Inserm U999: Fabrice Antigny Anaïs Saint-Martin